Article

Visual field impairment associated with vehicle accident rate

A recent cohort study indicates that older individuals with glaucoma drive at least as safely as other individuals of that age without the disease.

Chicago-A recent cohort study indicates that older individuals with glaucoma drive at least as safely as other individuals of that age without the disease. However, a nested case control study of drivers from the first study showed that moderate-to-severe impairment in the central 24° field of their worse eye is associated with an increased risk of being involved in a vehicular crash, said Cynthia Owsley, MSPH, PhD, professor of ophthalmology, University of Alabama at Birmingham.

In the first study, Dr. Owsley and colleagues used accident reports and other means to compare the at-fault crash rate of 516 drivers over age 50 diagnosed with glaucoma and that of 115 drivers who did not have the disease.

“There was no difference in the at-fault crash rates of drivers with and without glaucoma,” she said.

These findings suggest that mandatory reporting of drivers diagnosed with glaucoma to state motor vehicle departments would be an inefficient way of identifying at-risk drivers, Dr. Owsley concluded.

However, results of the nested cohort study, which included calculation of Advanced Glaucoma Intervention Study (AGIS) scores, suggest that certain drivers with glaucoma are at higher risk of involvement in accidents. Drivers with AGIS scores in the worse eye indicating severe corneal visual impairment were six times more likely to be involved in an at-fault crash and four times more likely to incur a crash regardless of fault.

“The AGIS score is a practical, useful marker,” Dr. Owsley said.

The score can signify a point in disease progression at which the physician and patient should begin discussing driver safety. And since the score is easily, routinely computed from automated perimetry tests used in glaucoma management, there is no additional patient or financial burden incurred when practices use it in the interest of public safety, she explained.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.